Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 2
2009 1
2010 3
2011 4
2012 2
2013 1
2014 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Ten years with biologics: to whom do data on effectiveness and safety apply?
Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J. Simard JF, et al. Among authors: coster l. Rheumatology (Oxford). 2011 Jan;50(1):204-13. doi: 10.1093/rheumatology/keq326. Epub 2010 Nov 16. Rheumatology (Oxford). 2011. PMID: 21084326
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L. Askling J, et al. Among authors: coster l. Ann Rheum Dis. 2007 Oct;66(10):1339-44. doi: 10.1136/ard.2006.062760. Epub 2007 Jan 29. Ann Rheum Dis. 2007. PMID: 17261532 Free PMC article.
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Cöster L, Forslind K, van Vollenhoven R, Heimbürger M. Chatzidionysiou K, et al. Among authors: coster l. RMD Open. 2016 Jan 14;2(1):e000133. doi: 10.1136/rmdopen-2015-000133. eCollection 2016. RMD Open. 2016. PMID: 26819752 Free PMC article.
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N. Askling J, et al. Among authors: coster l. Arthritis Rheum. 2005 Jul;52(7):1986-92. doi: 10.1002/art.21137. Arthritis Rheum. 2005. PMID: 15986370 Free article.
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Askling J, et al. Among authors: coster l. Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941. Arthritis Rheum. 2009. PMID: 19877027 Free article.
14 results